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Supplementary Legends 
 
Figure S1. Localization of Methyl-Arginine mark (SYM10) and WDR77 in 
embryonic testes.  
Methyl-Arginine marks were visualized using the SYM10 antibody. The SYM10 
antibody stains nuclei including a prominent structure inside the nucleus. WDR77 
is predominantly localized in the nucleus. Neither SYM10 nor WDR77 signals co-
localize with cytoplasmic MIWI2 granules. 
 
Figure S2. Localization TDRDs and Mael in 20 day-old Miwi KO testes 
The localization of TDRD1, TDRD6, TDRD7, and TDRD9 in chromatoid bodies is 
not altered by MIWI loss in 20 days old testes. 
 
Figure S3. Protein coverage of MILI and MIWI by mass spectrometry for the 
identification of methylarginine residues 
The amino acid sequence coverage of (A) MIWI and (B) MILI, identified residues 
are labeled in red. 
 
Figure S4. Representative informative spectra for the identification of 
peptides containing methylarginine 
(A) The CID spectrum of MILI peptide 547-LTR@WGLSLHKD-556 is shown 
(where @ represents di-methylation), Xcorr=3.4 and peptide probability 
(PP)=99%; (B) The ETD spectrum of LTR@WGLSLHKD is shown, Xcorr=3.9 
and Sf=0.97; (C) The CID spectrum of MILI peptide 134-
ASVGWSRMLGR@GSSE-148 is shown, Xcorr=2.4 and PP=96%; this 
identification failed to pass our stringent filtering criteria but the CID spectra was 
used to determine the symmetry of the di-methylation. (D) The ETD spectrum of 
ASVGWSRMLGR@GSSE is shown, Xcorr=3.6 and Sf=0.93. In both peptides, 
the type of methylation was determined to be symmetric using a method 
described previously (Wang et al. 2009a). 
 
Figure S5. Ectopically expressed MIWI and MILI contain symmetrical 
methylarginine 
Myc tagged MIWI or MILI proteins were expressed in and immunoprecipitated 
from 293 cell using anti-myc beads and tested by Western blotting with SYM10 
antibodies; non-transfected cells were used as a negative control.  
 
Supplementary Tables 
Table S1. List of proteins identified by MudPIT analysis of 3xFLAG-HA-MIWI 
complexes precipitated from mouse testes 
Selected proteins identified with high confidence in 3xFLAG-HA-MIWI 
complexes, which were precipitated from testis extracts from 3-6 months old 
animals, non-transgenic animals were used as a negative control. The number of 
peptides and percent of coverage are shown separately for FLAG and HA 
elutions.  
 
Table S2. List of proteins identified by MudPIT analysis of 3xFLAG-HA-MILI 
and 3xFLAG-HA-MIWI2 complexes precipitated from mouse testes 
Selected proteins identified with high confidence in 3xFLAG-HA-MILI and 
3xFLAG-HA-MIWI2 complexes, which were precipitated from testis extracts from 
E16.5-18.5 embryos; non-transgenic animals were used as a negative control. 
The number of peptides and percent of coverage are shown only for FLAG 
elution. 
Supplementary Methods 
Immunofluorescence detection of protein localization  
For immunofluorescence in frozen sections, testis were fixed in freshly prepared 
2% PFA in PBS before embedding in OCT blocks. Sections were cut at 8 um 
thickness and stored at -80 C. After thawing, the sections were washed for 5 
minutes in PBS to remove OCT and then for 20 min with 0.1% Triton-X-100 in 
PBS to promote antibody penetration. Blocking, incubation with primary and 
secondary antibodies and staining for DNA was performed as for paraffin 
sections and described in (Aravin et al. 2008). For imaging, a laser-scanning 
confocal microscope (Zeiss) was used. 
 
Preparation of samples for MudPIT  
For immunoprecipitation of endogenous MIWI and MILI complexes, we dissected 
20 testes from 3-6 months old C57BL/6 animals. Testes were homogenized in 
2mL ice-cold extraction buffer (10mM HEPES pH7.0, 100mM KCl, 1.5mM MgCl2, 
2mM EDTA, 1.5mM DTT, 1% Triton-100, 10% glycerol, 0.5% NP40, complete 
mini EDTA free, proteinase inhibitor (Roche 11836 170001), RNasin) with 40 
strokes. Lysates were centrifuged at 14,000 rpm for 30 minutes, at 4 Cº. The 
supernatant was filtered through a 45 µm filter (Millipore, SLHV033RB) and 
diluted with 4 volumes of NT2 buffer (25mM Tris-HCl pH7.5, 150mM NaCl, 
1.5mM MgCl2, 1mM DTT, 0.05% NP40, complete mini EDTA free, proteinase 
inhibitor (Roche 11836 170001), RNasin) containing a 1:100 dilution of MILI N1 
(against DPVRPLFRGPTPVHPSQ), MILI N2 (against VRKDREEPRSSLPDPS ), 
MIWI N2 (against MTGRARAR peptide), MIWI N3 (PTEGDLVGRGRQRGM) 
antibodies, or rabbit control IgG. The incubation with antibodies was performed 
for 12 hours at 4 Cº with rotation. Afterward, lysates were incubated with Protein-
A beads (Sigma) for 4 hours at 4 Cº with rotation. Beads were washed once with 
NT2 buffer (containing 150mM NaCl), once with NT2 buffer (containing 300mM 
NaCl), and one time with NT2 (containing 150mM NaCl without NP40), each time 
for 10 minutes at 4 Cº. MIWI and MILI immunocomplexes were eluted twice with 
500 µL of 100mM glycine pH2.2 with agitation for 15 minutes each time at 4 Cº. 
The eluate was precipitated with 20% TCA (final concentration) at 4 Cº for 12 
hours. It was then spun at 14,000 rpm for 15min, 4 Cº.  Pellets were washed 
twice with ice cold acetone, dried for 2 minutes in speed-vac to remove the 
residual acetone (Wolters et al. 2001). 
For immunoprecipitation of FLAG-HA-tagged MIWI, MILI and MIWI2 complexes, 
transgenic animals were used; non-transgenic CD-1 animals were used as 
controls. Immunoprecipitations of FLAG-HA-MIWI2 and MILI complexes were 
performed from 16.5-18.5 days old embryos obtained from crosses of CD-1 non-
transgenic females with FLAG-HA-MIWI2 or FLAG-HA-MILI transgenic males. 
Testes were manually dissected and homogenized in extraction buffer (10mM 
HEPES pH7.0, 100mM KCl, 1.5mM MgCl2, 2mM EDTA, 1.5mM DTT, 1% Triton-
100, 10% glycerol, 0.5% NP40, complete mini EDTA free, proteinase inhibitor 
(Roche 11836 170001), RNasin or 300 µg/ml RNaseA) with 40 strokes. Lysates 
were incubated at room temperature for 5 minutes then centrifuged at 14,000 
rpm for 30 minutes, at 4 Cº. The supernatant was filtered through a 45 µm filter 
(Millipore, SLHV033RB) diluted with 4 volumes of NT2 buffer (25mM Tris-HCl 
pH7.5, 150mM NaCl, 1.5mM MgCl2, 0.05% NP40, complete mini EDTA free, 
proteinase inhibitor (Roche 11836 170001), RNasin or 300 µg/ml RNaseA) 
containing 300 µL FLAG beads suspension (Anti-FLAG M2 agarose from mouse 
A2220-5ML, Sigma) and incubated for 4 hours at 4 Cº with rotation. The beads 
were washed with NT2 buffer (containing 150mM NaCl) for 10 minutes, and once 
with NT2 buffer (containing 300mM NaCl) for 10 minutes at 4 Cº with rotation. 
The FLAG elution was performed twice in 500µL NT2 buffer with 0.5mg/mL 
3xFLAG peptide (Sigma) for 2 hours at 4Cº with agitation. Half of the FLAG 
eluate was precipitated with 20% TCA in final volume at 4 Cº for 12 hours. The 
rest was incubated with 1mL NT2 buffer, containing 150 µL HA beads 
suspension (Anti-HA Affinity Matrix 11815016001, Roche) for 4 hours at 4 Cº with 
rotation. Beads were washed NT2 buffer (containing 150mM NaCl) for 10 
minutes, once with NT2 buffer (containing 300mM NaCl) for 10 minutes at 4 Cº 
with rotation, and one time with NT2 (containing 150mM NaCl without NP40). 
The immunoprecipitated complexes were eluted twice with 500 µL of 100mM 
glycine pH2.2 with agitation for 15 minutes each time at 4 Cº. Afterward, TCA 
precipitation was performed essentially as described for endogenous MIWI and 
MILI antibodies. For FLAG-HA-MIWI FLAG eluted and HA eluted samples were 
sent separately for MudPIT analysis; we performed only FLAG elution for FLAG-
HA-MIWI2 and FLAG-HA-MILI due to the small amount of material.  
 
Identification of MA-positions by Nano-LC/Orbitrap CID/ETD  
A nano-LC system consisting of a Spark Endurance autosampler (Emmen, 
Holland) and four Eksigent direct-flow capillary/nano LC pumps (Dublin, CA) that 
were powered by pressurized nitrogen (100 p.s.i) was used for the separation of 
MA-peptides. The nano-LC flow path was lab-made and included two Vici 10-port 
low-dead-volume valves (Houston, TX). A lab-made dynamic flow nano-spray 
interface was used to couple the nano-LC system to a Thermo Scientific 
LTQ/ETD or to a LTQ/Orbitrap (San Jose, CA). Mobile phase A consisted of 
0.04% formic acid in 3% acetonitrile and mobile phase B was 0.04% formic acid 
in 80% acetonitrile.  The digests of purified proteins were loaded onto a reverse-
phase (RP) peptide trap (5 mm x 300 µm I.D., Agilent, Palo Alto, CA) at a flow 
rate of 10 µL/min and then washed with mobile phase A for 3 minutes. The trap 
was then switched online, and a lab-packed reversed-phase nano C-18 column 
was employed for separation. The column consisted of 3 µm reversed-phase 
particles packed in a 25 cm long, 360 µm O.D. and 75µm I.D. fused silica 
capillary terminated with a non-coated tapered tip of 2-3 µm diameter. The flow 
rate was 250 nL/min and the gradient consisted of: (i) a linear increase from 0 to 
7% B over 5 min; (ii) an increase from 7 to 19% B over 85 min; (iii) an increase 
from 19 to 60% B in 25 min, and finally (iv) isocratic at 60% B for 10 min. 
 
For LTQ/ETD, the MS was working in data-dependent mode; one scan cycle was 
comprised of an MS1 scan (m/z range from 300-2000 with a target value of 
3x104) followed by six sequential dependent MS2 scans (the target value was 
1x104 and the maximum injection time was 250 ms), with the 1st-3rd scans using 
CID for the top 3 most intensive precursors and 4th-6th scans using ETD for the 
same set of ions. For CID, the activation time was 30 ms and the normalized 
activation energy was 35%; For ETD, a mixture of ultrapure helium and nitrogen 
(25% Helium and 75% nitrogen, purity >99.995%) was used as the reaction gas. 
To obtain efficient fragmentation, the device was modified to reach a high anion 
target value (2x106) easily; the ETD reaction time was set at 120 ms and 
supplemental activation was employed to enhance the fragmentation efficiency 
for doubly-charged precursors. For Orbitrap analysis, one scan cycle included a 
MS1 scan (m/z 300-2000) at a resolution of 100,000 followed by three MS2 
scans (resolution at 30,000) to fragment the three most abundant precursors 
found in the MS1 spectrum. The target values for MS1 and MS2 by Orbitrap 
were, respectively, 2x106 and 2x105. To ensure mass accuracy, the Orbitrap 
analyzer was calibrated on the same days that the experiments were performed. 
For both LTQ/ETD and Orbitrap experiments, dynamic exclusion was used with 
one repeat counts, 35s repeat duration, and 100s exclusion duration. We 
employed an offline precursor matching approach to obtain accurate m/z and 
charge states of the MA-peptides putatively identified by LTQ/ETD, as described 
previously (Duan et al. 2009).   
 
Spectra generated by ETD were processed using BioWorks software (3.3.1, 
Thermo Scientific), which incorporates the SEQUEST algorithm, to find the best 
matching sequences. Briefly, the charge states of the precursors of ETD spectra 
were assigned by the Charger program (Thermo Scientific) and then searched 
against a database containing the sequence of both proteins. Differential 
modifications of MMA (+14.0156 Da) and DMA (+28.0313 Da) on Arg residues 
were considered. The resulting identifications of all proteolytic peptides were first 
filtered by the precursor masses (<5ppm), and then using the scores of Xcorr 
(Cross-correlation score; 2+ precursor ≥2.5, 3+ ≥ 3.2, 4+ ≥ 3.8) and the Sf scores 
(final score, ≥ 0.8); peptide probabilities for CID-identified peptides must be larger 
than 95%. For each putatively identified MA-peptide, final confirmation was 
obtained by manual inspection of the spectrum for fragment ions.   
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Table S1
3xFLAG-HA-MIWI non-transgenic animal
Proteins which are identified in IP FLAG elution HA elution FLAG elution HA elution motifs/function CB component
TUDOR PROTEINS
TDRD1 64(32.8%) 38(18.2%) 0 0 Tudor motif binds with dimethyl R yes
TDRD2 27(38.2%) 17(16.1%) 0 0 Tudor motif binds with dimethyl R ?
TDRD4 12(8.7%) 8(6%) 0 0 Tudor motif binds with dimethyl R yes
TDRD6 136(37.9%) 117(26.1%) 0 0 Tudor motif binds with dimethyl R yes
TDRD7 3(2.1%) 0 0 0 Tudor motif binds with dimethyl R yes
TDRD9 2(2.1%) 0 0 0 Tudor motif binds with dimethyl R yes
SYMMETRIC METHYL ARGININE TRANSFERASE COMPLEX
PRMT5 55(36.3%) 20(18.4%) 115(53.1%) 0 dimethyl arginine transferase ?
WDR77 26(39.5%) 14(21.6%) 87(56.7%) 0 PRMT5 partner yes
RNA HELICASES
DDX4/MVH 33(29.6%) 23(15.2%) 3(4.1%) 0 DEAD box RNA helicase yes
Mov10L 18(10.6%) 26(16.1%) 0 0 DEAD box RNA helicase ?
DDX1 5(8.4%) 0 0 0 DEAD box RNA helicase ?
DDX39 3(8%) 0 0 0 DEAD box RNA helicase ?
DDX25 9(17.3%) 0 0 0 DEAD box RNA helicase yes
eIF4a3/DDX48 4(9.5%) 0 0 0 DEAD box RNA helicase/slicing factor ?
DDX5/p68 12(15.9%) 3(4.4%) 0 0 DEAD box RNA helicase/Drosha partner in miRNA and rRNA processing ?
DDX17/p72 10(10.6%) 0 0 0 DEAD box RNA helicase/Drosha partner in miRNA and rRNA processing ?
DDX15 2(3.7%) 0 0 0 DEAH-box RNA helicase/splicing factor ?
DDX9 16(11.1%) 0 0 0 DEAH-box RNA helicase ?
Ruv-B PROTEINS
Ruv-B like2 28(38.2%) 55(37.6%) 3(6%) 0 ATPase and DNA helicase ?
Ruv-B like1 47(52.2%) 28(26.1%) 13(29.2%) 0 ATPase and DNA helicase ?
CHAPERONES
DnaJ A2(Hsp40) 24(41.3%) 42(36.2%) 2(7%) 0 DNA J domain ?
DnaJ C7(Hsp40) 16(23.3%) 14(18.4%) 2(4.7%) 0 DNA J domain ?
DnaJ A1 (Hsp40) 29(43.1%) 18(16.4%) 0 0 DNA J domain ?
DnaJ B11 (Hsp40) 5(18.2%) 6(15.1%) 0 0 DNA J domain ?
HSP70-2 264(55.5%) 200(41.2%) 66(43%) 0 Hsp70 protein ?
HSP70-1 10(13.1%) 166(48%) 67(25.5%) 0 Hsp70 protein ?
HSP70-5 102(42.7%) 108(37.7%) 52(38.3%) 0 Hsp70 protein ?
HSPA8 176(45.7%) 121(38.5%) 57(37.2%) 0 Hsp70 protein ?
HSP90 70(42.5%) 50(25.1%) 3(5.7%) 0 Hsp90 protein ?
HSPA4L 54(40.5%) 45(30.5%) 16(19.1%) 0 Hsp70 protein ?
HSP70 L1 68(25.1%) 60(22.8%) 17(14.7%) 0 Hsp70 protein ?
HSP70 1B 32(14.8%) 39(17.4%) 7(9.3%) 0 Hsp70 protein ?
HSP DNAJ-like 4 24(36%) 9(16%) 0 0 DNA J domain ?
HSPA4 5(5.1%) 3(5%) 0 0 Hsp70 protein ?
HSPA9 8(15.9%) 13(13.8%) 0 0 Hsp70 protein ?
HSPD1 2(3.5%) 0 0 0 chaperonin_like superfamily ?
CTT5 9(19.2%) 8(12.2%) 4(5.9%) 0 chaperonin_like superfamily ?
CTT4 11(13.5%) 7(15.6%) 3(4.1%) 0 chaperonin_like superfamily ?
CTT3 4(8.3%) 12(14.9%) 0 0 chaperonin_like superfamily ?
CTT6A 5(8.7%) 5(8.9%) 0 0 chaperonin_like superfamily ?
CTT8 10(14.6%) 13(21%) 0 0 chaperonin_like superfamily ?
CTT7 8(8.8%) 4(10.7%) 2(3.7%) 0 chaperonin_like superfamily ?
CTT2 7(9.5%) 4(10.8%) 0 0 chaperonin_like superfamily ?
CTT6 6(9.4%) 0 0 0 chaperonin_like superfamily ?
FK506 BINDING PROTEINS
FK506BP6 28(40.7%) 26(32.7%) 0 0 FKBP-type peptidyl-prolyl cis-trans isomerase ?
FK506BP5 21(29.2%) 9(14.3%) 0 0 FKBP-type peptidyl-prolyl cis-trans isomerase ?
TRANSLATION 
nuclear cap binding protein subunit 2 4(13.5%) 0 0 0 RRM ?
nuclear cap binding protein subunit 1 10(13%) 0 0 0 RRM, P-body component ?
eIF4E 8(16.6%) 5(13.8%) 0 0 RRM ?
PABP cytoplasmic 1 211(59.1%) 48(25.8%) 39(26.6%) 0 RRM,Poly-adenylate binding protein, unique domain ?
PABP cytopasmic 2 99(26.3%) 0 20(15.1%) 0 RRM,Poly-adenylate binding protein, unique domain yes
PABP cytoplasmic 4 isoform1 85(18.2%) 0 0 0 RRM,Poly-adenylate binding protein, unique domain
siRNA PATHWAY
Ago1 2(1.9%) 0 0 0 core RNAi component/PAZ and PIWI motifs ?
Ago2 2(1.9%) 0 0 0 core RNAi component/PAZ and PIWI motifs yes
Ago3 2(1.9%) 0 0 0 core RNAi component/PAZ and PIWI motifs yes
Ago4 2(1.9%) 0 0 0 core RNAi component/PAZ and PIWI motifs ?
VIG/Serbp1 10(14.5%) 0 0 0 Hyaluronan / mRNA binding family ?
FXR1 8(20.6%) 0 0 0 K homology RNA-binding domain, type I
Mov10 3(5.4%) 0 0 0 DEAD box RNA helicase ?
piRNA PATHWAY
MIWI 2804(87.1%) 1007(52%) 11(15%) 0 core component piRNA complex/PAZ and PIWI motif yes
MILI 24(36%) 9(16.1%) 0 0 core component piRNA complex/PAZ and PIWI motif yes
MAEL 6(12%) 3(9%) 0 0 HMG protein yes
NOT SORTED
PARC 243(49.6%) 64(12.3%) 0 0 anaphase-promoting complex, subunit 10;IBR domain;cullin ?
valosin 12(13%) 7(11.8%) 0 0 P-loop containing Nucleoside Triphosphate Hydrolases,CDC48 domain 2 ?
DNA REPLICATION
mcm3 85(47.4%) 99(38.4%) 0 0 P-loop containing Nucleoside Triphosphate Hydrolases ?
mcm5 91(45.9%) 37(25.3%) 0 0 P-loop containing Nucleoside Triphosphate Hydrolases ?
RNA METABOLISM
SSB(Sjogren syndrome antigen B) 3(9.4%) 2(6%) 0 0 RRM ?
Rpap3 9(15.5%) 16(20.6%) 0 0 RNA polymerase II associated protein 3 ?
Adad2 6(17.4%) 2(4%) 0 0 Adenosine-deaminase (editase) domain, dsRNA binding motif ?
Yb2 107(52.9%) 44(33%) 16(22.4%) cold shock domain ?
ELAV 13(36.2%) 0 0 0 RRM ?
ubiquitin-specific protease 19 4(6%) 0 0 0 ?
histone deacetylase 6 35(21.9%) 13(9.9%) 12(12.6%) 0 stress granules component ?
Table S2
transgenic animal non-transgenic animal
Proteins which are identified in IP FLAG-MIWI2 FLAG-MILI FLAG elution motifs/function CB component
TUDOR PROTEINS
TDRD1 10(8.9%) 12(13%) 0 Tudor motif binds with dimethyl R yes
TDRD2 21(32.9%) 0 0 Tudor motif binds with dimethyl R ?
TDRD9 6(5.8%) 0 0 Tudor motif binds with dimethyl R yes
SYMMETRIC METHYL ARGININE TRANSFERASE COMPLEX
PRMT5 66(33%) 12(19.3%) 28(26.7%) dimethyl arginine transferase ?
WDR77 63(40.1%) 21(40.1%) 28(34.8%) PRMT5 partner yes
RNA HELICASES
Mov10L 4(2.4%) 0 0 DEAD box RNA helicase ?
DDX1 16(18.9%) 33(34.6%) 25(21.4%) DEAD box RNA helicase ?
DDX5/p68 33(28.5%) 71(46.5%) 67(40%) DEAD box RNA helicase/Drosha partner in miRNA and rRNA processing ?
DDX17/p72 10(14.8%)) 15(17.5%) 7(8.6%) DEAD box RNA helicase/Drosha partner in miRNA and rRNA processing ?
DDX46 13(8.3%) 8(10.4%) 10(11.1%) DEAD box RNA helicase ?
DDX21 5(7.8%) 0 0 DEAD box RNA helicase ?
DDX4 9(7.7%) 0 0 DEAD box RNA helicase yes
DDX41 2(5.3%) 0 0 DEAD box RNA helicase ?
DDX50 7(8.9%) 10(8.2%) 9(7.1%) DEAD box RNA helicase ?
DDX9 25(12%) 0 21(12.7%) DEAH box RNA helicase ?
DDX38 12(7%) 0 8(9.9%) DEAH box RNA helicase ?
DDX29 6(5.4%) 0 2(2%) DEAH box RNA helicase ?
DDX57 8(7%) 0 4(3.6%) DEAH box RNA helicase ?
DDX36 2(2.6%) 0 0 DEAH box RNA helicase ?
Ruv-B PROTEINS
Ruv-B like2 7(8.2%) 13(23.8%) 10(18.6%) ATPase and DNA helicase ?
Ruv-B like1 12(26.1%) 23(38.4%) 18(34.4%) ATPase and DNA helicase ?
CHAPERONES
DnaJ A2(Hsp40) 13(17.2%) 4(18%) 3(14.8%) DNA J domain ?
DnaJ C7(Hsp40) 11(15%) 5(5.9%) 0 DNA J domain ?
DnaJ A1 (Hsp40) 19(20.8%) 13(25.4%) 7(16.7%) DNA J domain ?
DnaJ B11 (Hsp40) 2(9.2%) 0 0 DNA J domain ?
DnaJ C2 (Hsp40) 4(9.5%) 5(11.6%) 4(11.1%) DNA J domain ?
DnaJ C3B (Hsp40) 4(11.9%) 0 0 DNA J domain ?
DnaJ C10 (Hsp40) 2(5.4%) 0 0 DNA J domain ?
DnaJ C9 (Hsp40) 0 4(24.7%) 0 DNA J domain ?
DnaJ A3(Hsp40) 0 3(7.9%) 0 DNA J domain ?
HSPA1B 16(12.1%) 17(14.2%) 7(11.4%) DNA J domain ?
HSPA8 153(48.8%) 111(54.5%) 70(37.6%) Hsp70 protein ?
Hsp90aa1 108(43.5%) 5(6.3%) 0 Hsp70 protein ?
HSP70 L1 68(25.1%) 60(22.8%) 17(14.7%) Hsp90 protein ?
HSPA9 8(9.4%) 14(11.4%) 0 DNA J domain ?
HSPD1 2(3.5%) 0 0 Hsp70 protein ?
HSPH1 2(4.7%) 0 0 Hsp70 protein ?
HSPB1 0 3(22.6%) 0 ?
CTT5 19(22.6%) 12(22.4%) 4(8.3%) chaperonin_like superfamily ?
CTT4 11(12.8%) 9(16.7%) 4(7.1%) chaperonin_like superfamily ?
CTT3 5(6.6%) 11(26.1%) 8(19.1%) chaperonin_like superfamily ?
CTT7 5(9.4%) 10(22.2%) 7(14.3%) chaperonin_like superfamily ?
CTT2 5(17.6%) 13(35.7%) 10(27.5%) chaperonin_like superfamily ?
FK506 BINDING PROTEINS
FK506BP6 66(44%) 4(14.4%) 6(16.5%) FKBP-type peptidyl-prolyl cis-trans isomerase ?
FK506BP5 8(13.6%) 0 0 FKBP-type peptidyl-prolyl cis-trans isomerase ?
FK506BP3 5(19.2%) 4(18.8%) 3(12.9%) FKBP-type peptidyl-prolyl cis-trans isomerase ?
TRANSLATION 
PABP cytoplasmic 4 31(22.5%) 40(29.6%) 33(24%) RRM,Poly-adenylate binding protein, unique domain ?
PABP nuclear 1 6(10.9%) 5(23.8%) 3(7.9%) RRM,Poly-adenylate binding protein, unique domain ?
PABP cytoplasmic 1 64(45.8%) 83(40.3%) 67(32.2%) RRM,Poly-adenylate binding protein, unique domain ?
eIF3 sub betta 27(52.6%) 67(71.4%) 58(67.4%) ?
eIF2 sub alpha 34(43.2%) 53(62.5%) 44(55.2%) ?
eIF3 sub 4 delta 29(46.9%) 47(49.7%) 44(49.7%0 ?
eEF2 110(48.9%) 118(55.6%) 175(50.3%) ?
siRNA PATHWAY
VIG/Serbp1 39(30.7%) 43(40%) 24(36.9%) Hyaluronan / mRNA binding family ?
FXR1 3(4.2%) 0 0 K homology RNA-binding domain, type I ?
Mov10 26(14.3%) 18(23%) 21(18.7%) DEAD box RNA helicase ?
Ago2 5(5.8%) 0 2 (2.4%) core RNAi component/PAZ and PIWI motifs yes
piRNA PATHWAY
MIWI2 143(42.8%) 2(3%) 0 core component piRNA complex/PAZ and PIWI motif yes
MILI 8(7.7%) 99(45.6%) 8(9.6%) core component piRNA complex/PAZ and PIWI motif yes
MAEL 2(8.1%) 0 0 HMG protein yes
DNA REPLICATION
mcm3 5(9.2%) 5(7.5%) 3(4.6%) P-loop containing Nucleoside Triphosphate Hydrolases ?
mcm5 5(5.3%) 3(4.9%) 5(5.3%) P-loop containing Nucleoside Triphosphate Hydrolases ?
mcm6 2(1.7%) 0 0 P-loop containing Nucleoside Triphosphate Hydrolases ?
RNA METABOLISM
Rpap3 9(15.5%) 16(20.6%) 0 RNA polymerase II associated protein 3 ?
Adad2 6(17.4%) 2(4%) 0 Adenosine-deaminase (editase) domain, dsRNA binding motif ?
Yb2 107(52.9%) 44(33%) 16(22.4%) cold shock domain ?
ELAV 10(24.7%) 20(44.5%) 14(31.9%) RRM ?
ribonuclease P/MRP 30kDa 2(9.7%) 3(11.2%) 0 RNase P subunit p30 ?
PRP4 pre-mRNA processing 5(12.9%) 3(10.9%) 0 A-kinase anchoring protein 95 ?
exosome component 5 4(16.2%) 3%(21.7%) 0 3' exoribonuclease family, domain 1. ?
exosome component 4 3(10.6%) 4(22.4%) 0 3' exoribonuclease family, domain 2 ?
exosome component 1 2(11.8%) 3(19%) 0 Ribosomal protein S1-like RNA-binding domain ?
exosome component 10 2(4.1%) 0 0 DnaQ-like exonuclease superfamily ?
exosome component 2 2(5.5%) 3(5.5%) 0 Ribosomal protein S1-like RNA-binding domain ?
